Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,414 across all filing types
Latest filing 2025-08-18 Transaction in Own Shar…
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares Classification · 100% confidence The document is a formal declaration of share buyback transactions ('Déclaration des transactions sur actions propres') by Sanofi. It provides a detailed table of daily aggregated transactions and a granular list of individual trades, including dates, volumes, prices, and the specific regulatory reference (MAR art.5 §2. (a)). This aligns perfectly with the definition for 'Transaction in Own Shares' (POS).
2025-08-18 English
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Juillet 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a standard French regulatory disclosure regarding the total number of voting rights and shares, as required by Article L. 233-8 II of the French Commercial Code and Article 223-16 of the AMF General Regulation. This type of filing is a recurring regulatory requirement for listed companies in France to update the market on their capital structure and voting rights. Since it does not fit into specific categories like 'Share Issue' (SHA) or 'Transaction in Own Shares' (POS) but is a mandatory regulatory disclosure, it is best classified as a Regulatory Filing (RNS).
2025-08-18 French
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares Classification · 100% confidence The document is a formal disclosure by Sanofi regarding the purchase of its own shares (share buyback) over a specific period (11 August 2025 to 15 August 2025). It includes aggregated daily data and a detailed transaction-by-transaction log, which is standard for 'Transaction in Own Shares' filings. This fits the definition of the POS category.
2025-08-18 English
Sanofi: Information concerning the total number of voting rights and shares - July 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal disclosure of the total number of voting rights and shares, explicitly citing Article L. 233-8 II of the French Commercial Code and Article 223-16 of the AMF General Regulation. This type of disclosure is a standard regulatory requirement for French listed companies to report share capital and voting rights structure. Since it does not fit into specific categories like 'Major Shareholding Notification' (which tracks individual investors) or 'Share Issue' (which details specific capital changes), it falls under the general regulatory filing category for periodic share/voting rights disclosures.
2025-08-18 English
Communiqué de presse : Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin dans l’UE pour la maladie liée aux IgG4
Regulatory Filings Classification · 95% confidence The document is a press release from Sanofi announcing that their drug 'rilzabrutinib' has received orphan drug designation from the EMA for IgG4-related disease. It provides details on clinical trial results, regulatory status, and background information on the drug and the disease. This type of corporate communication regarding product development, regulatory milestones, and clinical trial updates is classified as a Regulatory Filing (RNS) as it serves as a general corporate announcement that does not fit into specific financial reporting categories like 10-K, ER, or IP.
2025-08-14 French
Press Release: Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease
Regulatory Filings Classification · 95% confidence The document is a press release issued by Sanofi regarding a regulatory update (orphan drug designation) for one of its investigational pharmaceutical products, rilzabrutinib. It does not constitute a financial report, a shareholder meeting document, or a mandatory regulatory filing of a specific form type. As it is a general corporate announcement regarding product development and regulatory status, it falls under the 'Regulatory Filings' (RNS) category as the appropriate fallback.
2025-08-14 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.